Clinical trials: Pulmonary Function; COPD
Pulmonary Disease, Chronic Obstructive
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COPD is a progressive disease characterized by increasing obstruction to airflow and the progressive development of respiratory symptoms including chronic cough, increased sputum production, dyspnea and wheezing.
- Trial name
- NCT03474081
- Testing
- FF/UMEC/VI, Tiotropium, Albuterol/salbutamol
- Where
- 72 sites in United States, Poland and 1 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
COPD, Interstitial Lung Disease
Autologous Stem Cell Treatment for Chronic Lung Disease Study
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day.
- Trial name
- NCT03044431
- Testing
- Cell therapy
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Lung Institute
Pulmonary Disease, Chronic Obstructive
A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
The objective of this study is to assess the daily variation in bronchodilator response to an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting anticholinergic (ipratropium) individually and…
- Trial name
- NCT01691482
- Testing
- Albuterol/salbutamol, Ipratropium
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.
This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- MOVE (NCT01996319)
- Testing
- QVA149
- Where
- 30 sites in Germany
- Volunteers
- 194 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC, administered once daily by the RESPIMAT Inhaler after 6 weeks of treatment.
- Trial name
- NCT01559116
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with…
- Trial name
- NCT01323621
- Testing
- Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Salbutamol as needed
- Where
- 51 sites in United States, Germany and 4 more
- Volunteers
- 512 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)
The primary objective of this Non Interventional Study is to measure changes in physical functioning, a surrogate for physical activity and exercise capacity, in COPD patients on treatment with Spiolto® Respimat® in routine daily…
- Trial name
- NCT02720757
- Testing
- Spiolto Respimat
- Where
- 6 sites in Belgium, Denmark and 4 more
- Volunteers
- 132 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients…
- Trial name
- NCT00144339
- Testing
- tiotropium
- Where
- 490 sites in United States, Argentina and 35 more
- Volunteers
- 5,993 people
- Sponsor
- Boehringer Ingelheim
CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA
Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)
Patients with chronic obstructive pulmonary disease (COPD) experience breathing difficulties because the airways deep in their lungs become narrowed. COPD patients use inhaler drugs to provide relief from breathlessness.
- Conditions
- CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, HEALTHY SUBJECTS
- Trial name
- NCT01721291
- Testing
- SALBUTAMOL
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Imperial College London
COPD, Chronic Musculoskeletal Pain
BRAIN, Symptoms, and Physical Activity in COPD
Persons with COPD have both chronic musculoskeletal pain and dyspnea that require accurate diagnosis and treatment, ultimately to optimize functional status.
- Trial name
- BRAIN-SPA (NCT04291131)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease, COPD
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT02449018
- Testing
- QBW251
- Where
- 16 sites in United States, Poland
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
- Trial name
- NCT00358436
- Testing
- Aclidinium bromide
- Where
- 120 sites in United States, Argentina and 5 more
- Volunteers
- 804 people
- Sponsor
- AstraZeneca